Brief: Galapagos Initiates Phase 3 Program With Filgotinib

Lakefront Biotherapeutics NV

26/04/2023 23:23

April 26 (Reuters) - Galapagos NV  GLPG.AS :
    * GALAPAGOS INITIATES PHASE 3 PROGRAM WITH FILGOTINIB IN
PATIENTS
WITH ACTIVE AXIAL SPONDYLOARTHRITIS
    * GALAPAGOS NV - RESULTS FROM PHASE 2 TORTUGA STUDY SHOWED
THAT
FILGOTINIB 200MG WAS EFFICACIOUS AND WELL-TOLERATED IN PATIENTS
WITH R-AXSPA

Source text for Eikon:  ID:nGNX1kS1FD 
Further company coverage:  GLPG.AS 

 ((Reuters.Briefs@thomsonreuters.com;))